Format

Send to

Choose Destination
Nat Rev Endocrinol. 2017 Apr;13(4):195-207. doi: 10.1038/nrendo.2016.205. Epub 2017 Jan 20.

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Author information

1
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065 New York, USA.
2
Weill Cornell Medical College, 1300 York Avenue, New York, 10065 New York, USA.

Abstract

Advances in cancer therapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two co-inhibitory receptors that are expressed on activated T cells against which therapeutic blocking antibodies have reached routine clinical use. Immune checkpoint blockade can induce inflammatory adverse effects, termed immune-related adverse events (IRAEs), which resemble autoimmune disease. In this Review, we describe the current data regarding immune-related endocrinopathies, including hypophysitis, thyroid dysfunction and diabetes mellitus. We discuss the clinical management of these endocrinopathies within the context of our current understanding of the mechanisms of IRAEs.

PMID:
28106152
PMCID:
PMC5629093
DOI:
10.1038/nrendo.2016.205
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center